Geron shares surge 10.74% intraday as federal court dismisses securities class action and RYTELO receives global approvals.

Geron surged 10.74% intraday, following the dismissal of a securities class action lawsuit by the U.S. District Court for the Northern District of California on March 30, 2026, which ruled that plaintiffs failed to prove fraudulent intent regarding the commercialization of RYTELO. Additionally, the company's core product, RYTELO (imetelstat), was approved by the FDA in June 2024 for the treatment of low-risk myelodysplastic syndromes and by the European Commission in March 2025, making it the first telomerase inhibitor for blood cancer.